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Abstract: Asthmatic patients with fixed airway obstruction (FAO) and
patients with chronic obstructive pulmonary disease (COPD) share
similarities in terms of irreversible pulmonary function impairment.
Exhaled nitric oxide (eNO) has been documented as a marker of airway
inflammation in asthma, but not in COPD.
To examine whether the basal eNO level and the change after
exercise may differentiate asthmatics with FAO from COPD, 27 normal
subjects, 60 stable asthmatics, and 62 stable COPD patients were
studied. Asthmatics with FAO (n¼ 29) were defined as showing a
postbronchodilator FEV1/forced vital capacity (FVC) 70% and FEV1
less than 80% predicted after inhaled salbutamol (400mg). COPD with
dynamic hyperinflation (n¼ 31) was defined as a decrease in inspiratory
capacity (DIC%) after a 6 minute walk test (6MWT).
Basal levels of eNO were significantly higher in asthmatics and
COPD patients compared to normal subjects. The changes in eNO after
6MWT were negatively correlated with the percent change in IC
(r¼0.380, n¼ 29, P¼ 0.042) in asthmatics with FAO. Their levels
of basal eNO correlated with the maximum mid-expiratory flow
(MMEF % predicted) before and after 6MWT. In COPD patients with
air-trapping, the percent change of eNO was positively correlated to
DIC% (rs¼ 0.404, n¼ 31, P¼ 0.024).
We conclude that asthma with FAO may represent residual inflam-
mation in the airways, while dynamic hyperinflation in COPD mayFang Sheng, BScN ung, MD,
Han-Pin Kuo, MD, PhD
(Medicine 95(15):e3400)
Abbreviations: 6MWT = 6 minute walk test, AHR = airway
hyperresponsiveness, COPD = chronic obstructive pulmonary
disease, DH = dynamic hyperinflation, eNO = exhaled nitric
oxide, FAO = fixed airway obstruction, FEV1 = forced expiratory
volume in 1 second, FVC = forced vital capacity, IC = inspiratory
capacity, ICS = inhaled corticosteroid, MMEF = maximum mid-
expiratory flow.
INTRODUCTION
A sthma is defined as a disease of reversible airflow obstruc-tion but it is known that many patients with asthma also can
end up with irreversible airflow obstruction.1 In contrast to
asthma, chronic obstructive pulmonary disease (COPD) is
characterized by the presence of airflow limitation that is not
fully reversible and is usually progressive, regardless of ade-
quate therapy.2 Distinctive patterns of airway inflammation and
structural changes underlie the pathology of the 2 diseases.3,4
However, there are limited methods to differentiate patients
with severe asthma from patients with COPD. The phenotypic
differences between COPD and asthma can be difficult to
differentiate and recently the term ‘‘asthma-COPD overlap
syndrome’’ has been used.5 Both static (resulting from
decreased elasticity of the lung parenchyma) and dynamic
effects (occurring when patients commence inhalation before
full exhalation has been achieved) of breathing contribute to
lung hyperinflation in COPD,6,7 which contributes to airflow
obstruction. A proportion of adult asthmatic patients with poor
response to treatment develops persistent airflow limitation
despite appropriate bronchodilator therapy.1 One of the earliest
approaches to phenotyping asthma in a clinically relevant
manner was to use the inflammatory cell composition of
induced sputum.8,9 Patients may be separated into eosinophilic
or noneosinophilic phenotypes according to the analysis of
sputum cells. Although inflammatory processes have been
associated with the presence of airway hyperresponsiveness
(AHR) in subjects with asthma, a positive response to the
bronchodilators was found to be predictive of AHR in patients
with persistent allergic asthma.10 Some asthmatics with per-
sistent airway obstruction demonstrate impaired bronchodilator
response presumed to be secondary to structural changes of
airway remodeling which may result from persistent airway
inflammation.11 This group of patients may clinically mimic
COPD patients who also demonstrate airflow limitation and
reduced bronchodilator response.5), while produced by airway epithelial
thelial cells, or inflammatory cells, has
involved in the bronchoconstriction,
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inflammation, and remodeling airway changes in asthmatics.12
Measurements of exhaled nitric oxide (eNO) levels are con-
sidered to be a valuable marker of airway inflammation12 and
elevated in the exhaled breath of asthmatic patients.13 The level
of eNO has been reported to correlate with bronchoconstrictor
response to methacholine,14 and to be associated with the degree
of decrease in forced expiratory volume in 1 second (FEV1)
during exercise.15,16 These data suggest that eNO level is likely
to reflect both inflammation, as well as airflow limitations.17
Previously, quantification of dynamic hyperinflation (DH)
due to airflow limitation has been derived from the complex use
of on-line measurement of inspiratory capacity (IC) from flow-
volume loops.18 The 6 minute walk test (6MWT) now has been
widely used as an objective measurement of functional status in
patients with respiratory impairment.19 During the 6MWT,
incremental exercise causes increased minute ventilation prim-
arily as a function of increases in tidal volume, and the increase
in respiratory frequency at higher levels of exercise has been
used to estimate DH in patients.18,20
However, since the levels of eNO before and after exercise
in asthmatic and COPD patients remain to be poorly charac-
terized,12 we determined whether this could be used to detect
DH. The aim of this study was to examine whether measure-
ments of eNO prior to or after the 6MWT could be used as a
marker of DH in COPD and asthma patients, and help to
differentiate these 2 groups of patients in order to inform on
treatment strategy.
METHODS
Study Population
This was a control, prospective study. Asthmatic and
COPD patients, aged between 40 and 80 years and who are
not current smokers or exsmokers, were recruited from out-
patient clinics of Chang Gung Memorial Hospital, Linkuo
Medical Center in Taiwan. Patients who were previously diag-
nosed with bronchiectasis, cystic fibrosis, upper airways
obstruction, bronchiolitis related to systemic disease, recent
upper respiratory tract infection, or use of antibiotics within the
last 6 weeks were excluded.
Sixty patients with asthma (aged 57.8 2.1 years, 21
women and 39 men) were documented with a clinical history
of reversible airways obstruction with an increase in FEV1 of
12% ormore than 200mL.21 Patients were clinically stable for
at least 3 months and were either on inhaled corticosteroids
(ICSs) alone, or combination of ICS and inhaled long-acting b2
agonist, or combination of ICS, long-acting b2 agonist, and
inhaled long-acting muscarinic antagonist. Patients discontin-
ued their regular medicine for 24 hours, prior to performing
spirometry before and after bronchodilator inhalation, and a
6MWT. 6MWT was done 2 days after spirometry. Asthmatic
patients were divided into 2 groups: the fixed airway obstruction
(FAO) group was defined as having postbronchodilator FEV1/
FVC 0.70 and FEV1 (% predicted) less than normal limit
(FAO group, n¼ 29) and those with no fixed airflow obstruction
had FEV1/FVC> 0.70 and FEV1 within normal limit (non-FAO
group, n¼ 31). These definitions were irrespective of the
magnitude of FEV1 changes after administration of 400mg
salbutamol.22
Sixty-two patients diagnosed with COPD (aged 71.2 1.2
Huang et alyears, all 62 men) had a postbronchodilator FEV1 between 30%
and 80% of predicted, with a postbronchodilator FEV1/FVC
ratio of 0.70, and a bronchodilator response of less than
2 | www.md-journal.com200mL or less than 12% change from baseline values.23
Patients were stable for at least 3 months and were taking their
regular medication (shown in Table 2) before entry into
the study.
Twenty-seven healthy volunteers (aged 51.2 2.9 years,
15 women and 12 men) had normal lung function, negative
methacholine challenge testing, negative serum specific IgE
(Phadiatop), normal total IgE level, as well as blood eosinophil
counts. Those with evidence of allergic rhinitis or asthma
were excluded.
The institutional review board of Chang Gung Memorial
Hospital approved the study. All participants gave their written
informed consent.
Exhaled NO Measurements
eNO was measured by NIOX MINO (Aerocrine AB,
Sweden), a hand-held device, and can detect eNO as low as
5 ppb.24 To exclude nasally produced NO, the participant
exhaled against a fixed resistance resulting in closure of the
velopharyngeal aperture. Ambient temperature and humidity
were measured prior to testing. Participants received eNO
measurements prior to and immediately after 6MWT.
Six Minute Walk Test
6MWT was performed according to ATS guidelines.19
Clinical staff educated all participants and explained the modi-
fied Borg dyspnea score before the test. Participants were asked
to walk back and forth in a 35m corridor. At each minute during
the walk, a physiotherapist told participant the remaining time
and gave encouragement. The participant stopped walk at the
end of 6 minutes, and walking distance was recorded. Pulmon-
ary function test, IC, and dyspnea score were recorded before
and after walking. Heart rate and oxygen saturation were
observed through the whole procedure. Spirometric parameters,
including forced vital capacity (FVC), FEV1, maximum mid-
expiratory flow (MMEF, FEF25%–75%), FEV1/FVC, IC, and
together with eNO measurements, were performed before
and at the end of 6MWT. DH after 6MWT was measured as
change of IC (DIC).20
Statistical Analysis
Data are reported as meanSEM. Continuous variables
were compared between groups using Student t test or the
Mann–WhitneyU test. Comparison between groups of category
data was done using Fisher exact test, or the Chi-square method.
Correlation between percent change of eNO and IC, or MMEF
predicted value before and after 6MWT was calculated by
Pearson or Spearman test. Statistical analysis was performed
by using the Prism 6 software (GraphPad Software, Inc., La
Jolla, CA). Significance was accepted at a P value less
than 0.05.
RESULTS
Characteristics of Study Population
Twenty-seven normal subjects, 60 patients with asthma,
and 62 COPD patients participated in this study (Table 1).
Healthy control subjects and asthmatics were significantly
younger than those of COPD. Patients with COPD had a lower
Medicine  Volume 95, Number 15, April 2016body mass index, IC, and change of oxygen saturation after
walking compared to healthy controls and asthmatics. FVC,
FEV1, and MMEF (% predicted) were significantly different
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Demographic Data
Normal Subjects Asthma COPD
Number 27 60 62
Gender, maley 12 39 62,
Age, years 51.2 2.9 57.8 2.1 71.2 1.2,
BMI, kg/m2 25.1 0.7 24.5 0.4 22.8 0.6,
FVC, L 2.7 0.2 2.6 0.1 2.1 0.1,
FVC, % pred. 92.8 3.1 86.5 2.5 78.8 2.5
FEV1, L 2.2 0.2 1.7 0.1 1.2 0.1,
FEV1, % pred. 93.8 3.8 73.7 3.2 62.2 3.3,
FEV1/FVC, % 82.2 1.9 65.1 1.6 55.9 1.9,
MMEF, % pred. 68.0 4.7 36.2 2.6 24.9 2.0,
IC before 6MWT, L 1.9 0.1 1.9 0.1 1.6 0.1,
DIC, % 7.9 3.7 1.3 2.5 0.9 2.2
Walking distance, m 518.1 14.1 491.7 14.5 392.2 14.3,
O2 saturation, pre-6MWT, % 96.9 0.3 96.1 0.2 95.4 0.3
DO2 saturation, % 9.2 2.3 7.1 0.7 13.2 1.2,
Data express as meanSEM. P< 0.05, P< 0.01 compared to normal subjects, P< 0.05, P< 0.01 compared to patients with asthma.
BMI¼ bodymass index, COPD¼ chronic obstructive pulmonary disease, FEV1¼ forced expiratory volume in 1 second, FVC¼ forced vital capacity,
WT
Medicine  Volume 95, Number 15, April 2016 eNO in Asthma and COPD After 6MWTamong groups. COPD patients walked a significantly lower
distance (392.2 14.3m, n¼ 62, P< 0.01) than normal sub-
jects (518.1 14.1m, n¼ 27) and asthmatics (491.7 14.5m,
n¼ 60).
Exhaled NO (eNO) Before and After 6MWT
Patients with asthma (30.4 2.9 ppb, n¼ 60, P¼ 0.003) or
COPD (27.1 2.5 ppb, n¼ 62, P¼ 0.009) had higher levels of
eNO than normal participants (18.3 1.4 ppb, n¼ 27) at base-
line (Figure 1A). A significant decrease in the change of eNO
level after 6MWT was found in patients with COPD
(7.2 3.9%, n¼ 62, P¼ 0.016) compared to the asthma group
IC¼ inspiratory capacity, MMEF¼maximum mid-expiratory flow, 6M
yAnalyzed by Chi-square test.(1.1 2.8%, n¼ 60, Figure 1B).
To analyze the difference in the response of eNO changes
after walking between the patients with asthma and COPD, we
FIGURE 1. (A) Levels of eNO before 6MWT in normal participants (n
COPD patients (COPD, n¼62). The horizontal line is mean. (B) Cha
patients with asthma (asthma, n¼60), and in COPD patients (COP
obstructive pulmonary disease, eNO¼ exhaled nitric oxide, 6MWT¼
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.categorized asthmatics into FAO and non-FAO. COPD patients
were divided into those with exercise-induced DH with
(DIC< 0%; n¼ 31) or those without (DIC 0%, n¼ 31)20
(Table 2). The baseline characteristics of FAO and non-FAO
asthmatics were not different except for lower lung function
including FVC, FEV1, MMEF (% predicted), and IC in FAO
compared to non-FAO (Table 2). A higher proportion of
asthmatics with FAO received combination therapy, whereas
more non-FAO asthmatics were on ICSs alone (Table 2). There
were no significant differences in terms of clinical character-
istics and lung function between COPD patients with or without
exercise-induced DH, except that the walking distance was
¼ 6 minute walk test.lower in those with DH compared to those without DH.
No difference of eNO level before and after 6MWT was
found in healthy controls (Figure 2A), and in asthma with non-
ormal, n¼27), in patients with asthma (asthma, n¼60), and in
nge in eNO after 6MWT in normal subjects (normal, n¼27), in
D, n¼62). Data are expressed by mean SEM. COPD¼ chronic
6 minute walk test.
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TABLE 2. Clinical Characteristics of Different Groups of Patients With Asthma or COPD
Asthma COPD
Non-FAO FAO P DIC 0% DIC< 0% P
Number 31 29 31 31
Gender, male

19 20 0.595 31 31 1.000
Age, years 54.9 3.1 60.9 2.7 0.155 72.1 1.6 70.9 1.8 0.616
BMI, kg/m2 25.0 0.7 23.9 0.5 0.225 22.7 0.8 22.5 0.7 0.852
FVC, L 3.0 0.2 2.1 0.1 0.0001 2.1 0.1 2.2 0.2 0.622
FVC, % pred. 97.9 3.0 73.9 2.4 <0.0001 77.7 3.0 80.1 4.2 0.643
FEV1, L 2.2 0.1 1.2 0.1 <0.0001 1.1 0.1 1.2 0.1 0.810
FEV1, % pred. 91.3 2.9 55.0 3.2 <0.0001 62.0 4.5 62.6 4.8 0.930
FEV1/FVC, % 73.6 1.4 56.1 1.9 <0.0001 57.5 2.9 54.5 2.4 0.438
MMEF, % pred. 49.6 3.1 21.8 2.2 <0.0001 27.1 3.2 22.4 2.5 0.245
IC before 6MWT, L 2.2 0.1 1.6 0.1 <0.0001 1.5 0.1 1.7 0.1 0.079
DIC, % 2.1 3.0 0.4 3.9 0.738 11.8 2.6 13.8 1.7 <0.0001
Walking distance, m 517.9 22.7 463.7 16.3 0.060 423.6 11.6 357.4 23.9 0.015
O2 saturation, pre-6MWT, % 96.7 0.3 95.5 0.4 0.012 95.5 0.4 95.4 0.3 0.764
DO2 saturation, % 6.8 0.9 7.4 1.1 0.648 13.4 1.6 12.8 1.7 0.823
Medication over previous yeary 0.002 0.884
ICS alone, n 15 5 0 0
ICS with LABA, n 16 19 10 9
LAMA, n 0 0 6 7
ICS with LABA and LAMA, n 0 5 15 15
Data express as meanSEM. BMI¼ body mass index, COPD¼ chronic obstructive pulmonary disease, FAO¼fixed airway obstruction,
FEV1¼ forced expiratory volume in 1 second, FVC¼ forced vital capacity, IC¼ inspiratory capacity, ICS¼ inhaled corticosteroid, LABA¼
long-acting b2 agonist, LAMA¼ long-acting muscarinic antagonist, MMEF¼maximum mid-expiratory flow, 6MWT¼ 6 minute walk test.
Huang et al Medicine  Volume 95, Number 15, April 2016FAO (Figure 2B) or FAO (Figure 2C) but the level of eNO after
walking was significantly reduced from 29.6 4.4 to
24.8 2.8 ppb in COPD patients with DH (n¼ 31, P¼ 0.006,
Figure 2D), but not observed in COPD patients without DH
(Figure 2E).
Delta eNO Correlated to Delta IC Before and
After 6MWT
There was no association between delta eNO% and delta
IC% after walking (r¼0.208, n¼ 27, P¼ 0.299) in normal
subjects. For asthmatic patients, there was a significant negative
correlation between delta eNO% and lower delta IC% in the
FAO group (r¼0.380, n¼ 29, P¼ 0.042, Figure 3A),
whereas a significant positive correlation between delta
eNO% and delta IC% in the non-FAO group (r¼ 0.414,
n¼ 31, P¼ 0.021, Figure 3B). There were significantly inverse
associations between the delta eNO% andMMEF (% predicted)
before exercise (r¼0.475, n¼ 29, P¼ 0.009, Figure 4A) or
after exercise (r¼0.485, n¼ 29, P¼ 0.008, Figure 4B) in
asthmatics with FAO, but not in the non-FAO group. There was
no correlation between the delta eNO% and the % predicted
value of FEV1 or the percent change of FEV1 before or after
6MWT in asthma either with FAO or without FAO. The base-
line levels of eNO before walking were positively correlated to
percent-predicted MMEF prior to (r¼ 0.467, P¼ 0.011) and
after (r¼ 0.587, P¼ 0.008) 6MWT in the FAO asthma group,

Analyzed by Fisher exact test.
yCalculated by Chi-square test for trend.but not in the non-FAO group.
There was a significant positive correlation between delta
eNO% and delta IC% after walking in COPD patients with DH
4 | www.md-journal.com(DIC< 0%, rs¼ 0.404, n¼ 31, P¼ 0.024, Figure 5B), but not in
COPD patients without DH (Figure 5A). We also observed a
significant positive correlation between delta eNO% and per-
cent-predicted MMEF before (rs¼ 0.373, n¼ 31, P¼ 0.039) or
after (rs¼ 0.393, n¼ 31, P¼ 0.029) walking in COPD patients
with DH, but not in COPD without DH. However, there was no
correlation between the delta eNO% and the % predicted value
of FEV1 at baseline or the percent change of FEV1 caused by the
6MWT in COPD patients either with DH or without DH.
DISCUSSION
We demonstrated that asthmatic patients can be separated
into 2 groups according to different responses in eNO levels
(delta eNO%) after 6MWT as function of IC (delta IC%)
changes before and after exercise. Thus, in asthma patients
with FAO, the delta eNO% negatively correlated with the delta
IC%, whereas there was a significant positive correlation
between delta eNO% and delta IC% in asthma patients without
FAO. There was an inverse association between the delta eNO%
and MMEF (% predicted) before or after 6MWT in asthmatics
with FAO, but not in the non-FAO group. However, in COPD
patients with DH after exercise, the delta eNO% positively
correlated with the delta IC%. The different pattern of eNO
changes after 6MWT is possibly related to the underlying
inflammatory mechanisms. In asthmatic patients with FAO,
there may be residual inflammation in the airways, with a
resultant increased eNO level after exercise. In contrast, asth-
matics without FAO had less airway inflammation and their
eNO level after exercise was related to expiratory airflow
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. The level of eNO was measured prior to and after 6MWT in normal subjects (A) (n¼27), asthma patients with non-FAO (B)
(n¼31) or FAO (C) (n¼29), and COPD patients with (D) (DIC<0%, n¼31) or without (E) (DIC0%, n¼31) dynamic hyperinflation on
pulm
Medicine  Volume 95, Number 15, April 2016 eNO in Asthma and COPD After 6MWTlimitation. On the other hand, in COPD patients with DH, air-
trapping during exercise may lead to the retention of NO in the
distal airspaces.
Assessing airway and lung inflammation is important for
investigating the underlying mechanisms of asthma and COPD.
exercise. The P value is indicated. COPD¼ chronic obstructive
obstruction, 6MWT¼6 minute walk test.In our study, the baseline eNO was higher in asthmatics
and COPD subjects than in normal subjects (Figure 1A),
thus indicating the presence of persistent airway or lung
FIGURE 3. Correlation between the delta eNO% and the delta IC% in
group (B). The number and significance are indicated. eNO¼ exha
capacity.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.inflammation in stable asthmatic and COPD patients. Since
airflow limitation is one contributing factor to final eNO
measurements,12,16 6MWT clearly evoked airflow limitation
and DH during exercise.20,25 Exercise-induced variations in
airway and alveolar eNO parameters revealed significantly
onary disease, eNO¼ exhaled nitric oxide, FAO¼ fixed airwaydifferent patterns of asthma and COPD. The clinical usefulness
of 6MWT to discriminate NO gas exchange in patients with
asthma and COPD remains to be established, and the
the asthmawith FAO group (A) as well in the asthmawith non-FAO
led nitric oxide, FAO¼ fixed airway obstruction, IC¼ inspiratory
www.md-journal.com | 5
ict
ted
Huang et al Medicine  Volume 95, Number 15, April 2016contribution of peripheral smaller airways/alveolar compart-
ments governing the increase or decrease in eNO after walking
exercise remains to be determined.
There is evidence to support that eNO emanates from
central and/or peripheral airways in asthmatics, and that these
levels reflect the presence of airway inflammation, particularly
eosinophilic inflammation.12 The levels of delta eNO after
exercise in asthma with FAO were increased as the decrease
of IC after walking exercise, which may result from the
narrowing airway by submaximal exercise of 6 minute walking.
Our results are different from a previous report that eNO
decreases during exercise-induced bronchoconstriction in chil-
dren with asthma.16 One might have expected that the associ-
ation between the delta eNO and delta IC is similar in COPD
FIGURE 4. Correlations between the delta eNO% and percent-pred
asthmatics with FAO. The number and significance are indica
MMEF¼maximum mid-expiratory flow.and asthma with FAO. However, opposite results were
observed. Asthma with FAO may have increased infiltration
of the airways with eosinophils and CD4þ lymphocytes, which
FIGURE 5. Percent changes in IC% correlate with exhaled eNO%
(DIC0%, A) and with dynamic hyperinflation (DIC<0%, B). The nu
pulmonary disease, eNO¼ exhaled nitric oxide, IC¼ inspiratory capa
6 | www.md-journal.comis accompanied by airway remodeling characterized by vaso-
dilatation, microvascular leakage, and smooth muscle hyper-
trophy, thus these changes may play a role in the pathogenesis of
fixed airflow obstruction.26,27 The role of the small airways in
producing airflow obstruction and AHR may be greater than
that of larger airways.28,29 In asthma with FAO, the basal level
of eNO before walking or change of delta eNO after walking is
positively correlated with the severity of MMEF, a parameter
reflective of small airways obstruction.30,31 Peripheral airway
narrowing is a major determinant of airflow obstruction,
because of more inflammation and increased smooth muscle
mass, which exhibits increased contractility.32–34 In addition,
increased inflammation as evidenced by infiltration of inflam-
matory cells and upregulation of cytokines could be considered
edMMEF (% predicted) before exercise (A) and after exercise (B) in
. eNO¼ exhaled nitric oxide, FAO¼ fixed airway obstruction,as the basis for the increased levels of eNO in small airways of
asthma with FAO.11,13 Therefore, high levels of eNO retained in
the small airways, where increased levels of eNO correlated
after walking in COPD patients without dynamic hyperinflation
mber and significance are indicated. COPD¼ chronic obstructive
city.
Copyright # 2016 Wolters Kluwer Health, Inc. All rights reserved.
23. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for thewith the decrease of IC after 6MWT in asthma with FAO. There
was no correlation between the delta eNO% and the % predicted
value of FEV1 or the percent change of FEV1 before or after
6MWT either in asthma with FAO or non-FAO. Thus, the small
airways may contribute significantly to the eNO level found in
asthma with FAO. In contrast, asthma with non-FAO may have
less small airway inflammation and AHR, as well as homo-
geneous structure with greater reversibility. The change of delta
eNO was negatively correlated to decreased IC in asthma with
no FAO, which may result from DH after 6MWT, as reported in
a previous study.16
In COPD, levels of eNO have been shown to be inversely
related to FEV1, to the carbon monoxide diffusion capacity
(DLCO), and to oxygen saturation (SaO2), and positively
correlated with the residual lung volume/total lung capacity
ratio.35,36 Other studies reported increased35,36 or reduced or
unchanged levels37,38 in stable COPD patients. Since pro-
gression of COPD from GOLD stage 0 to 4 is strongly associ-
ated with thickening of the small airway wall due to the
remodeling process,39 eNO production indicates that alveolar
concentration of NO in COPD patients may reflect airway
remodeling in addition to inflammation. Contrary to asthmatic
patients, in COPD patients with exercise induced air-trapping,
the percent change of eNO was positively correlated to delta IC
after 6MWT. It is hypothesized that the eNO possibly originates
from the peripheral airways in COPD patients,36 and this may
explain the decreased eNO in COPD subjects with air-trapping.
Since COPD patients presented with heterogeneous etiology, in
patients without exercise induced DH possibly represent a
different phenotype of COPD. An HRCT study may help to
identify different disease phenotypes based on structural
changes, such as centrilobular (small airway component) or
panlobular (parenchymal component) involvement.
One limitation of this study is the lack of the direct
evidence of exercise-induced bronchoconstriction in asthmatics
or COPD during the 6MWT. Further physiological observations
of flow rate or resistance are necessary. Another limitation of
the study is the lack of inflammatory evidence in the bronchi to
relate to the levels of eNO.
CONCLUSION
In conclusion, after a 6MWT, the elevated eNO resulted
from persistent inflammation in the small airways in asthma
with FAO, while the reduced eNO in COPD patients resulted
from air-trapping changes and retained NO in the distal air-
space. The eNO levels and DH changes after 6MWT may be
helpful in differentiating subgroups of asthma and COPD
patients that could be helpful in providing individualized
therapy.
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